Surgical Approach Does Not Influence Changes in Circulating Immune Cell Populations Following Lung Cancer Resection

Lung Cancer ◽  
2022 ◽  
Author(s):  
Nathaniel Deboever ◽  
Daniel J. McGrail ◽  
Younghee Lee ◽  
Hai T. Tran ◽  
Kyle G. Mitchell ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Approach ◽  
Immune Cell ◽  
Cell Populations ◽  
Cancer Resection

scholarly journals Nodal Upstaging During Lung Cancer Resection Is Associated With Surgical Approach

2016 ◽  
Vol 101 (1) ◽  
pp. 238-245 ◽  
Author(s):  
Jeremiah T. Martin ◽  
Eric B. Durbin ◽  
Li Chen ◽  
Tamas Gal ◽  
Angela Mahan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Approach ◽  
Cancer Resection ◽  
Nodal Upstaging

scholarly journals PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

2019 ◽  
Vol 20 (7) ◽  
pp. 1631 ◽  
Author(s):  
Ana Bocanegra ◽  
Gonzalo Fernandez-Hinojal ◽  
Miren Zuazo-Ibarra ◽  
Hugo Arasanz ◽  
Maria Garcia-Granda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Cell ◽  
Expression Profiles ◽  
Myeloid Cell ◽  
Predictive Biomarker ◽  
Cell Types ◽  
Immune Checkpoint Blockade ◽  
Cell Populations ◽  
Patient Stratification ◽  
Tumor Expression

PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, PD-L1 is widely expressed by many immune cell types, and little is known on the relevance of systemic PD-L1+ cells for responses to immune checkpoint blockade. We present two clinical cases of patients with non-small cell lung cancer (NSCLC) and PD-L1-negative tumors treated with atezolizumab that showed either objective responses or progression. These patients showed major differences in the distribution of PD-L1 expression within systemic immune cells. Based on these results, an exploratory study was carried out with 32 cases of NSCLC patients undergoing PD-L1/PD-1 blockade therapies, to compare PD-L1 expression profiles and their relationships with clinical outcomes. Significant differences in the percentage of PD-L1+ CD11b+ myeloid cell populations were found between objective responders and non-responders. Patients with percentages of PD-L1+ CD11b+ cells above 30% before the start of immunotherapy showed response rates of 50%, and 70% when combined with memory CD4 T cell profiling. These findings indicate that quantification of systemic PD-L1+ myeloid cell subsets could provide a simple biomarker for patient stratification, even if biopsies are scored as PD-L1 null.

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients

2019 ◽  
Vol 68 (10) ◽  
pp. 1585-1596 ◽  
Author(s):  
Estefanía Paula Juliá ◽  
Pablo Mandó ◽  
Manglio Miguel Rizzo ◽  
Gerardo Rubén Cueto ◽  
Florencia Tsou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Renal Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Renal Cell ◽  
Immune Cell ◽  
Small Cell ◽  
Cell Populations ◽  
Small Cell Lung

Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding

2020 ◽  
Vol 32 (2) ◽  
pp. 337-343 ◽  
Author(s):  
Robert M. Van Haren ◽  
Ravi Rajaram ◽  
Arlene M. Correa ◽  
Reza J. Mehran ◽  
Mara B. Antonoff ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Resection

scholarly journals SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma

2021 ◽  
Author(s):  
Lu Yuan ◽  
Xixi Wu ◽  
Longshan Zhang ◽  
Mi Yang ◽  
Xiaoqing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Lung Adenocarcinoma ◽  
Expression Profile ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Regulatory Pathways ◽  
Chronic Lung Diseases ◽  
Potential Biomarker

AbstractPulmonary surfactant protein A1 (SFTPA1) is a member of the C-type lectin subfamily that plays a critical role in maintaining lung tissue homeostasis and the innate immune response. SFTPA1 disruption can cause several acute or chronic lung diseases, including lung cancer. However, little research has been performed to associate SFTPA1 with immune cell infiltration and the response to immunotherapy in lung cancer. The findings of our study describe the SFTPA1 expression profile in multiple databases and was validated in BALB/c mice, human tumor tissues, and paired normal tissues using an immunohistochemistry assay. High SFTPA1 mRNA expression was associated with a favorable prognosis through a survival analysis in lung adenocarcinoma (LUAD) samples from TCGA. Further GeneOntology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses showed that SFTPA1 was involved in the toll-like receptor signaling pathway. An immune infiltration analysis clarified that high SFTPA1 expression was associated with an increased number of M1 macrophages, CD8+ T cells, memory activated CD4+ T cells, regulatory T cells, as well as a reduced number of M2 macrophages. Our clinical data suggest that SFTPA1 may serve as a biomarker for predicting a favorable response to immunotherapy for patients with LUAD. Collectively, our study extends the expression profile and potential regulatory pathways of SFTPA1 and may provide a potential biomarker for establishing novel preventive and therapeutic strategies for lung adenocarcinoma.

scholarly journals Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3828
Author(s):  
Anello Marcello Poma ◽  
Rossella Bruno ◽  
Iacopo Pietrini ◽  
Greta Alì ◽  
Giulia Pasquini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Durable Response ◽  
Nsclc Patients

Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we aimed at refining the selection of patients based on the expression of immune genes. Forty-six consecutive advanced NSCLC patients treated with pembrolizumab in first-line setting were enrolled. The expression levels of 770 genes involved in the regulation of the immune system was analysed by the nanoString system. PD-L1 expression was evaluated by immunohistochemistry. Patients with durable clinical benefit had a greater infiltration of cytotoxic cells, exhausted CD8, B-cells, CD45, T-cells, CD8 T-cells and NK cells. Immune cell scores such as CD8 T-cell and NK cell were good predictors of durable response with an AUC of 0.82. Among the immune cell markers, XCL1/2 showed the better performance in predicting durable benefit to pembrolizumab, with an AUC of 0.85. Additionally, CD8A, CD8B and EOMES showed a high specificity (>0.86) in identifying patients with a good response to treatment. In the same series, PD-L1 expression levels had an AUC of 0.61. The characterization of tumor microenvironment, even with the use of single markers, can improve patients’ selection for pembrolizumab treatment.

Sign in / Sign up

Export Citation Format

Share Document